Moderna Stock Quote Today

MRNA -  USA Stock  

USD 132.06  5.56  4.04%

Market Performance
1 of 100
Odds Of Distress
Less than 34
Moderna is trading at 132.06 as of the 24th of May 2022, a -4.04 percent decrease since the beginning of the trading day. The stock's open price was 137.62. Moderna has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Moderna are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2020 and ending today, the 24th of May 2022. Please note, there could be an existing legal relationship between Moderna (MRNA) and Adhera Therapeutics (ATRX). Click here to learn more.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 405.45 M outstanding shares of which 15.43 M shares are now shorted by private and institutional investors with about 2.74 trading days to cover. More on Moderna

Moderna Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Moderna's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Moderna or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Moderna has very high historical volatility over the last 90 days
Moderna has a strong financial position based on the latest SEC filings
About 64.0% of the company shares are owned by institutional investors
Latest headline from www.investors.com: Vaccine Stocks Pfizer, BioNTech Score A Win Leading Pfizer To Make A Bullish Move - Investors Business Daily
Moderna Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Moderna SEC Filings
Moderna SEC Filings Security & Exchange Commission EDGAR Reports
Related EntityATRX (Adhera Therapeutics)
CEORobert Moscato  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
Biotech
Average Analyst Recommendation
Analysts covering Moderna report their recommendations after researching Moderna's financial statements, talking to executives and customers, or listening in on Moderna's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Moderna. The Moderna consensus assessment is calculated by taking the average forecast from all of the analysts covering Moderna.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Moderna based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Moderna financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares339.6 M403 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted357 M431 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations14.7 B13.6 B
Significantly Up
Increasing
Slightly volatile
Total Assets26.6 B24.7 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities11.4 B10.5 B
Significantly Up
Increasing
Slightly volatile
Current Assets17.3 B16.1 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities9.8 B9.1 B
Significantly Up
Increasing
Slightly volatile
Total Debt760.7 M705 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.710.656
Significantly Up
Increasing
Slightly volatile
Gross Margin0.860.858
Slightly Up
Decreasing
Slightly volatile
Asset Turnover1.070.993
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Moderna's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Moderna's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Moderna's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moderna's financial leverage. It provides some insight into what part of Moderna's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Moderna's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Moderna deploys its capital and how much of that capital is borrowed.
Liquidity
Moderna cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 916 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

14.7 BillionShare
Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square and employs 2,700 people. Moderna is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 55.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Moderna conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 405.45 M outstanding shares of which 15.43 M shares are now shorted by private and institutional investors with about 2.74 trading days to cover. Moderna currently holds about 10.73 B in cash with 13.62 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.63.
Check Moderna Probability Of Bankruptcy
Ownership
Moderna maintains a total of four hundred five million four hundred fifty thousand outstanding shares. Over half of Moderna outstanding shares are owned by institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Moderna. Please watch out for any change in the institutional holdings of Moderna as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Moderna Ownership Details

Moderna Stock Price Odds Analysis

What are Moderna's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Moderna jumping above the current price in 90 days from now is about 89.47%. The Moderna probability density function shows the probability of Moderna stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8289. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Moderna will likely underperform. Additionally, the company has an alpha of 0.2236, implying that it can generate a 0.22 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 132.06HorizonTargetOdds Above 132.06
10.47%90 days
 132.06 
89.47%
Based on a normal probability distribution, the odds of Moderna to move above the current price in 90 days from now is about 89.47 (This Moderna probability density function shows the probability of Moderna Stock to fall within a particular range of prices over 90 days) .

Moderna Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.
InstituionSecurity TypeTotal SharesValue
Baillie Gifford CoCommon Shares45.6 M7.9 B
Blackrock IncCommon Shares28.7 M4.9 B
Susquehanna International Group LlpCall Options4.2 M716.5 M
Susquehanna International Group LlpPut Options3.9 M669.8 M
View Moderna Diagnostics

Moderna Historical Income Statement

Moderna Income Statement is one of the three primary financial statements used for reporting Moderna's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moderna revenue and expense. Moderna Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M. View More Fundamentals

Moderna Stock Against Markets

Picking the right benchmark for Moderna stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Moderna stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Moderna is critical whether you are bullish or bearish towards Moderna at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Moderna Corporate Directors

Moderna corporate directors refer to members of a Moderna board of directors. The board of directors generally takes responsibility for the Moderna's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Moderna's board members must vote for the resolution. The Moderna board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Nancy Phelan - DirectorProfile
Philip Ranker - DirectorProfile
Joseph Ramelli - Independent DirectorProfile
Tim Boris - DirectorProfile

Investing Moderna

You need to understand the risk of investing before taking a position in Moderna. The danger of trading Moderna is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Moderna is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Moderna. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Moderna is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.